AngioDynamics (ANGO)
(Real Time Quote from BATS)
$7.40 USD
-0.08 (-1.07%)
Updated Jul 24, 2024 11:08 AM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANGO 7.40 -0.08(-1.07%)
Will ANGO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANGO
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
ANGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
Other News for ANGO
Reaffirmed Buy Rating on AngioDynamics: A Strategic Assessment of Growth and Valuation Prospects
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Argenx Se (ARGX) and AngioDynamics (ANGO)
AngioDynamics price target lowered by $5 at Canaccord, here's why
AngioDynamics: Lumpy Progress Is Still Progress
AngioDynamics Inc (ANGO) Q4 2024 Earnings Call Transcript Highlights: Strong MedTech Growth ...